SPI-1005 in Adults Receiving Cochlear Implant (NCT06340633)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SPI-1005 in Adults Receiving a Cochlear Implant
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical trial is to learn about the effects of drug SPI-1005 in adults receiving a cochlear implant with a long electrode array (FLEX26 or greater) from MED-EL Cochlear Implant Systems into one ear. The main question this clinical trial aims to answer is: Is drug SPI-1005 safe and well-tolerated in adults receiving a cochlear implant, and/or what medical problems might participants experience when taking drug SPI-1005? The clinical trial will also measure the effects of SPI-1005 on hearing, word recognition, speech discrimination, tinnitus, and vertigo outcomes after receiving a cochlear implant. The purpose for this and future clinical trials is to learn whether SPI-1005 can prevent or treat these side effects after receiving a cochlear implant. Participants will take drug SPI-1005 or placebo (a look-alike substance that contains no drug) for 6 months, starting 2 days before receiving the cochlear implant. There are 5 required in-clinic visits over 6 months for audiology and other tests. The effects of SPI-1005 will be compared to the placebo (the look-alike substance that contains no drug) to study what effects SPI-1005 might have.
Who can join: Review the eligibility criteria below.
Location: University of Iowa — Iowa City, Iowa
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (6 Sites)
- University of Iowa — Iowa City, Iowa
- Ohio State University — Columbus, Ohio
- Thomas Jefferson University — Philadelphia, Pennsylvania
- Medical University of South Carolina — Charleston, South Carolina
- University of Texas Southwestern — Dallas, Texas
- Medical College of Wisconsin — Milwaukee, Wisconsin
📞 Contact the Study Coordinator
Phone: (206) 634-2559
Email: info@soundpharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hearing Loss
- Improving Outcomes Using Technology for Children Who Are DHH — Aurora, Colorado
- Safety and Efficacy of a Drug Eluting Slim Modiolar Electrode Array — Los Angeles, California
- Wind Noise Sound Quality Preference and Claims Study — Kitchener, Ontario
- Hearing Outcomes With the Nucleus® 8 Sound Processor and Nucleus® 7 Sound Processor in Adult Veteran and Non-veteran Cochlear Implant Recipients — Lone Tree, Colorado
- Evaluation of Investigational Hearing Instrument Features — Aurora, Illinois
- Automated Text Message Reminders to Promote Hearing Aid Adoption — Stanford, California
Explore by condition: All Hearing Loss clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.